Purchase this article with an account.
Peter Ciechanowski, Marc Stahel, Frank Moser, Sandra Lortz, Heidi Fassnacht, Nicole Graf, Stephan Estermann, Matthias Becker, Stephan Michels; No IOP-Elevation in patients treated with Anti-VEGF ranibizumab for diabetic macular edema. Invest. Ophthalmol. Vis. Sci. 2013;54(15):2407.
Download citation file:
© ARVO (1962-2015); The Authors (2016-present)
Recent studies indicated an IOP-elevation in patients with age related macular degeneration secondary to Anti-VEGF therapy. Review of the IOP evolution in patients under Anti-VEGF treatment for diabetic macular edema (DME).
Retrospective analysis of IOP in patients with DME being under ranibizumab treatment between April 2011 and July 2012.
176 eyes with DME were treated with ranibizumab. At first presentation the mean IOP was 15.69mmHg whereas 19 eyes had a history of glaucoma. The mean number of injections was 3.85 till July 2012. Mean IOPs measured in April 2011 (+/- 3 months) and in July 2012 (+/- 3 months) were 15.36mmHg and 15.12mmHg respectively. The mean maximum IOP in the time period under ranibizumab treatment was 17.83mmHg, ranging from 10 to 33mmHg. 5 eyes had a maximum IOP of ≥ 25mmHg. Two eyes with maximum IOP > 30 had a history of glaucoma. Patients with a history of glaucoma had higher mean baseline IOP (17.78mmHg) and higher mean maximum IOP (20.83mmHg).
For DME patients without history of glaucoma no clinically relevant IOP changes were noticed under Anti-VEGF treatment with ranibizumab. A longterm follow up is planned.
This PDF is available to Subscribers Only